GRFS
Price
$9.08
Change
-$0.06 (-0.66%)
Updated
Jul 3 closing price
Capitalization
5.48B
23 days until earnings call
SNY
Price
$48.30
Change
-$1.01 (-2.05%)
Updated
Jul 3 closing price
Capitalization
122.61B
25 days until earnings call
Interact to see
Advertisement

GRFS vs SNY

Header iconGRFS vs SNY Comparison
Open Charts GRFS vs SNYBanner chart's image
Grifols SA
Price$9.08
Change-$0.06 (-0.66%)
Volume$191.16K
Capitalization5.48B
Sanofi ADS
Price$48.30
Change-$1.01 (-2.05%)
Volume$1.56M
Capitalization122.61B
GRFS vs SNY Comparison Chart in %
Loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRFS vs. SNY commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRFS is a Buy and SNY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (GRFS: $9.08 vs. SNY: $48.30)
Brand notoriety: GRFS and SNY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GRFS: 27% vs. SNY: 71%
Market capitalization -- GRFS: $5.48B vs. SNY: $122.61B
GRFS [@Pharmaceuticals: Major] is valued at $5.48B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRFS’s FA Score shows that 1 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • GRFS’s FA Score: 1 green, 4 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, GRFS is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRFS’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).

  • GRFS’s TA Score: 4 bullish, 5 bearish.
  • SNY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, SNY is a better buy in the short-term than GRFS.

Price Growth

GRFS (@Pharmaceuticals: Major) experienced а +6.70% price change this week, while SNY (@Pharmaceuticals: Major) price change was -0.14% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.19%. For the same industry, the average monthly price growth was +2.56%, and the average quarterly price growth was +9.33%.

Reported Earning Dates

GRFS is expected to report earnings on Jul 29, 2025.

SNY is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.19% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNY($123B) has a higher market cap than GRFS($5.48B). GRFS has higher P/E ratio than SNY: GRFS (68.68) vs SNY (20.80). GRFS YTD gains are higher at: 22.043 vs. SNY (4.583). SNY has higher annual earnings (EBITDA): 12.6B vs. GRFS (640M). SNY has more cash in the bank: 8.98B vs. GRFS (544M). GRFS has less debt than SNY: GRFS (11.1B) vs SNY (18.4B). SNY has higher revenues than GRFS: SNY (46.4B) vs GRFS (6.54B).
GRFSSNYGRFS / SNY
Capitalization5.48B123B4%
EBITDA640M12.6B5%
Gain YTD22.0434.583481%
P/E Ratio68.6820.80330%
Revenue6.54B46.4B14%
Total Cash544M8.98B6%
Total Debt11.1B18.4B60%
FUNDAMENTALS RATINGS
GRFS vs SNY: Fundamental Ratings
GRFS
SNY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
8775
PRICE GROWTH RATING
1..100
4259
P/E GROWTH RATING
1..100
9691
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRFS's Valuation (6) in the Pharmaceuticals Major industry is in the same range as SNY (7). This means that GRFS’s stock grew similarly to SNY’s over the last 12 months.

SNY's Profit vs Risk Rating (68) in the Pharmaceuticals Major industry is in the same range as GRFS (100). This means that SNY’s stock grew similarly to GRFS’s over the last 12 months.

SNY's SMR Rating (75) in the Pharmaceuticals Major industry is in the same range as GRFS (87). This means that SNY’s stock grew similarly to GRFS’s over the last 12 months.

GRFS's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as SNY (59). This means that GRFS’s stock grew similarly to SNY’s over the last 12 months.

SNY's P/E Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as GRFS (96). This means that SNY’s stock grew similarly to GRFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRFSSNY
RSI
ODDS (%)
Bearish Trend 3 days ago
69%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
39%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
53%
MACD
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
51%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
42%
Advances
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 4 days ago
51%
Declines
ODDS (%)
Bearish Trend 18 days ago
75%
Bearish Trend 18 days ago
49%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
56%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
45%
View a ticker or compare two or three
Interact to see
Advertisement
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
XEM.X0.0017980.000149
+9.02%
NEM cryptocurrency
PERL.X0.0003520.000013
+3.92%
PERL.eco cryptocurrency
CKB.X0.0034470.000072
+2.14%
Nervos Network cryptocurrency
SEI.X0.2617570.004624
+1.80%
Sei cryptocurrency
BAL.X0.953002-0.001836
-0.19%
Balancer cryptocurrency

GRFS and

Correlation & Price change

A.I.dvisor tells us that GRFS and BIIB have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and BIIB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
-0.66%
BIIB - GRFS
28%
Poorly correlated
-0.24%
GILD - GRFS
27%
Poorly correlated
+0.22%
GIFOF - GRFS
26%
Poorly correlated
N/A
SNY - GRFS
23%
Poorly correlated
-2.05%
AMRN - GRFS
20%
Poorly correlated
+0.48%
More

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with GSK. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
-2.05%
GSK - SNY
52%
Loosely correlated
-0.86%
NVS - SNY
48%
Loosely correlated
-1.54%
BIIB - SNY
47%
Loosely correlated
-0.24%
AZN - SNY
46%
Loosely correlated
-2.36%
PFE - SNY
46%
Loosely correlated
+0.24%
More